Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Amylin as a future obesity treatment introducing cagrilintideNote significant GI adverse effects cf. placebo but no apparent plateauing of weight loss after 26 weeks CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current